| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| GALECTIN THERAPEUTICS INC | Chief Medical Officer | Restricted Stock Unit | 40K | $71.4K | $1.79 | Jan 24, 2024 | Direct |
| GALECTIN THERAPEUTICS INC | Chief Medical Officer | Stock Option (right to buy) | 65K | Jan 24, 2024 | Direct | ||
| Protalix BioTherapeutics, Inc. | Director | Stock Options (Right to Buy) | 61.7K | Sep 29, 2023 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| GALT | GALECTIN THERAPEUTICS INC | Jan 24, 2024 | 2 | $0 | 4 | Feb 7, 2024 | Chief Medical Officer |
| PLX | Protalix BioTherapeutics, Inc. | Sep 29, 2023 | 1 | $0 | 4 | Oct 3, 2023 | Director |
| GALT | GALECTIN THERAPEUTICS INC | Jan 26, 2023 | 1 | $0 | 4 | Jan 30, 2023 | Chief Medical Officer |
| PLX | Protalix BioTherapeutics, Inc. | Sep 7, 2022 | 1 | $0 | 4 | Sep 9, 2022 | Director |
| GALT | GALECTIN THERAPEUTICS INC | Jan 24, 2022 | 1 | $0 | 4 | Jan 25, 2022 | Chief Medical Officer |